Cabazitaxel

  • 01 October 2010

Dr Sarah Cant, Head of Policy and Campaigns at The Prostate Cancer Charity, spoke to the Daily Mail and the Daily Telegraph, about cabazitaxel,  a new drug which could  give men with advanced prostate cancer two extra months of life. Cabazitaxel, which was developed by the Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, is due to be licensed in Europe in the next few months, after which the National Institute for Health and Clinical Excellence (NICE) will assess which NHS patients will have access to it.